{
    "nct_id": "NCT03524430",
    "official_title": "RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY / BREVITY-02 in Germany)",
    "inclusion_criteria": "Inclusion Criteria\n\n* Women aged at least 18 years;\n* Patients must be able to provide informed consent and sign the informed consent form to participate in the RDA study before any study procedures starts;\n* Newly diagnosed clinical stage I, II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal;\n* Tumour size at least 1 cm in one dimension by clinical or radiographic exam (WHO criteria);\n* Must have histological confirmation of invasive breast cancer of any subtype or grade;\n* Patient is scheduled for neoadjuvant chemotherapy +/- antibodies and +/- other drugs according to Standard of Care;\n* Patient willing to have 2 research core needle biopsies (for RDA) taken at 2 collection timepoints during neoadjuvant chemotherapy treatment.\n\nExclusion Criteria\n\n* Patient who has had prior local (i.e. surgery or radiotherapy) or systemic (i.e. endocrine or cytotoxic) therapy for the current breast cancer;\n* Participation in another interventional clinical trial with concurrent treatment with experimental drugs to treat the current breast cancer during the period of neoadjuvant therapy (from diagnosis until surgery);\n* Stage IV breast cancer;\n* Bilateral or multicentric breast tumour;\n* Prior malignant disease except curatively treated in-situ maligancies;\n* Concurrent pregnancy;\n* Breast feeding woman;\n* Concurrent medical, psychiatric or addictive disorders that may limit the ability to give informed consent or complete the trial;\n* Reasons indicating risk of poor compliance with study procedures;\n* Patient not able to consent;\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}